



## ASX RELEASE

### RESULTS OF ANNUAL GENERAL MEETING

**Sydney, November 17, 2011:** In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution on the agenda of this morning's Annual General Meeting.

#### Remuneration Report

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
255,086,736	11,499,319	592,548	364,842

The motion was carried as an ordinary resolution on a show of hands.

#### Re-election of Director - Mr Mel Bridges

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
259,407,699	2,751,037	5,204,817	8,051,011

The motion was carried as an ordinary resolution on a show of hands.

#### Issue of Options to Mr P Francis

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
246,717,548	20,336,195	392,982	903,062

The motion was carried as an ordinary resolution on a show of hands.

#### Issue of Options to Mr M Bridges

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
250,094,359	16,959,384	392,982	903,062

The motion was carried as an ordinary resolution on a show of hands.

### Issue of Options to Dr J Chaplin

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
250,090,077	16,456,466	900,182	903,062

The motion was carried as an ordinary resolution on a show of hands.

### Issue of Options to Mr I Ross

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
246,692,644	20,353,899	400,182	903,062

The motion was carried as an ordinary resolution on a show of hands.

### Change of Company Name

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
260,004,647	1,926,030	5,298,059	8,185,828

The motion was carried as a special resolution on a show of hands.

### For Further Information

Dr Peter French

[pfrench@benitec.com](mailto:pfrench@benitec.com)

Chief Executive Officer

Tel: +61 (0)412 457 595

### About Benitec [www.benitec.com](http://www.benitec.com)

Benitec Limited is developing novel treatments for chronic and life-threatening conditions based on gene silencing using a transformational technology; DNA-directed RNA interference (ddRNAi) - sometimes called expressed RNAi. The technology's potential to address unmet medical needs and, potentially, to cure disease results from its demonstrated ability to permanently silence genes which cause the condition.

Benitec now either owns or exclusively licences from CSIRO more than 40 granted or allowed patents in the field of RNA interference for human therapeutic applications. Patents have been granted in key territories such as the USA, the UK, Japan, Europe, Canada and Australia. In addition, Benitec has almost 50 patent applications pending for which it is the owner or exclusive licensee from CSIRO, and has further intellectual property under development as a result of its pipeline program.

Benitec trades on the Australian Securities Exchange (ASX) under the symbol "BLT". The Company was founded in 1997 and has been publicly held since 2001. The Company aims to deliver a range of novel ddRNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry. In-house it is pursuing a focused R&D strategy in infectious diseases, cancer and chronic cancer-associated pain, as well as programs with licensees that have advanced to pre-clinical and/or clinical trials.